Cancer Therapeutic Procedure
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment
Caribou Biosciences Discontinues CAR-NK Program, Lays Off 21 Employees to Focus on CAR-T Cell Therapies
Caribou Biosciences, CAR-NK, CAR-T, cell therapy, layoffs, biotech, cancer treatment, autoimmune diseases
AbbVie’s Epkinly Enters Follicular Lymphoma Market, Competing with Roche’s Lunsumio
Epkinly, Lunsumio, follicular lymphoma, bispecific antibodies, AbbVie, Roche, FDA approval, cancer treatment
iOnctura Secures €80 Million in Series B Financing to Advance Rare Eye Cancer Treatment
iOnctura, Series B financing, rare eye cancer, uveal melanoma, roginolisib, cancer treatment
Breakthrough in Lupus Treatment: CAR T-Cell Therapy Shows Promising Results
CAR T-cell therapy, lupus, autoimmune disease, cancer treatment, immunology
Ikena Oncology Cuts Hippo Pathway Inhibitor, Lays Off Half of Staff in Strategic Reprioritization
Ikena Oncology, Hippo pathway inhibitor, TEAD1-selective, layoffs, strategic update, biotech industry, clinical trials, cancer treatment
Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy
Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.
Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment
Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO
J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks
J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.
Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates
Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.